About
About Puma Biotechnology, Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Visit company website
5 years, 5 months ago
Puma Biotechnology, Inc is currently in a long term downtrend where the price is trading 19.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
Puma Biotechnology, Inc's total revenue sank by 16.4% to $53M since the same quarter in the previous year.
Its net income has dropped by 33.9% to $-15M since the same quarter in the previous year.
Finally, its free cash flow fell by 549.0% to $-6M since the same quarter in the previous year.
Based on the above factors, Puma Biotechnology, Inc gets an overall score of 1/5.